Takeda Pharmaceutical Co Ltd (TAK)
13.07
-0.16
(-1.21%)
USD |
NYSE |
Apr 25, 16:00
13.06
-0.01
(-0.08%)
After-Hours: 20:00
Takeda Pharmaceutical Net Income (Quarterly): 716.00M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 716.00M |
| September 30, 2023 | -332.51M |
| June 30, 2023 | 651.48M |
| March 31, 2023 | 235.71M |
| December 31, 2022 | 844.99M |
| September 30, 2022 | 446.94M |
| June 30, 2022 | 810.45M |
| March 31, 2022 | -97.77M |
| December 31, 2021 | 508.19M |
| September 30, 2021 | 417.60M |
| June 30, 2021 | 1.258B |
| March 31, 2021 | 1.861B |
| December 31, 2020 | 884.32M |
| September 30, 2020 | 38.04M |
| June 30, 2020 | 766.76M |
| March 31, 2020 | 15.83M |
| December 31, 2019 | -296.32M |
| September 30, 2019 | 631.45M |
| June 30, 2019 | 63.77M |
| March 31, 2019 | -265.54M |
| December 31, 2018 | 334.98M |
| September 30, 2018 | 434.46M |
| June 30, 2018 | 717.36M |
| March 31, 2018 | -498.34M |
| December 31, 2017 | 602.88M |
| Date | Value |
|---|---|
| September 30, 2017 | 252.69M |
| June 30, 2017 | 1.303B |
| March 31, 2017 | -446.18M |
| December 31, 2016 | 379.13M |
| September 30, 2016 | 242.03M |
| June 30, 2016 | 921.53M |
| March 31, 2016 | -290.57M |
| December 31, 2015 | 487.84M |
| September 30, 2015 | 243.92M |
| June 30, 2015 | 202.66M |
| March 31, 2015 | -1.893B |
| December 31, 2014 | 160.09M |
| September 30, 2014 | 269.75M |
| June 30, 2014 | 326.95M |
| March 31, 2014 | -258.81M |
| December 31, 2013 | 543.00M |
| September 30, 2013 | 432.93M |
| June 30, 2013 | 363.96M |
| March 31, 2013 | 105.01M |
| December 31, 2012 | 235.50M |
| September 30, 2012 | 409.84M |
| June 30, 2012 | 1.092B |
| March 31, 2012 | -460.05M |
| December 31, 2011 | 322.37M |
| September 30, 2011 | 772.91M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-332.51M
Minimum
Sep 2023
1.861B
Maximum
Mar 2021
495.99M
Average
508.19M
Median
Dec 2021
Net Income (Quarterly) Benchmarks
| Hoya Corp | 264.03M |
| Otsuka Holdings Co Ltd | -271.56M |
| Nxera Pharma Co Ltd | -1.409M |
| PeptiDream Inc | -3.424M |
| Stemcell Holdings Inc | 1.037M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 7.526B |
| Total Expenses (Quarterly) | 7.076B |
| EPS Diluted (Quarterly) | 0.2265 |
| Enterprise Value | 71.84B |
| Gross Profit Margin (Quarterly) | 65.85% |
| Profit Margin (Quarterly) | 9.51% |
| Earnings Yield | 3.07% |
| Operating Earnings Yield | 6.02% |
| Normalized Earnings Yield | 3.071 |